Eva Schaefer-Jansen | Head, IR |
Paul Hudson | CEO |
Bill Sibold | Global Business Unit Head |
Thomas Triomphe | Global Business Unit Head |
Olivier Charmeil | Global Business Unit Head |
Julie Van Ongevalle | Global Business Unit Head |
Jean-Baptiste de Chatillon | CFO |
John Reed | EVP, Global Head of Research & Development |
Wimal Kapadia | Bernstein |
Richard Vosser | JP Morgan |
Luisa Hector | Berenberg |
Simon Mather | Exane |
Graham Parry | Bank of America |
Tim Anderson | Wolfe |
Mark Purcell | Morgan Stanley |
Emmanuel Papadakis | Deutsche Bank |
Jo Walton | Credit Suisse |
Good morning, good afternoon, and good evening to everyone. Thank you for joining us to review Sanofi’s 2021 Fourth Quarter and Full Year Results followed by a Q&A session.
As usual, you can find the slides to this earnings call on the Investors page of our website at sanofi.com.
Moving to slide 3, I would like to remind you that information presented in this call contains forward-looking statements that involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially. I refer you to our Form 20-F document on file with the SEC and also our Document d’Enregistrement Universal for a description of these risk factors.